Clinical Trial Update: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One [Phase 3]

View source ↗

Summary

Phase 3 head-to-head trial comparing alemtuzumab with Rebif in relapsing-remitting multiple sclerosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Lemtrada (alemtuzumab)
• Rebif (interferon beta-1a)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2014-11-24